Whalesbook
HCG Gains Optimism on KKR Backing and Brokerage Buy Call
The strong fourth-quarter EBITDA growth and strategic investment from KKR are boosting confidence in HealthCare Global Enterprises (HCG). Prabhudas Lilladher's 'BUY' recommendation and ambitious ₹820 target price are based on anticipated improvements in operational efficiency and margin expansion. These are key areas for focus, as HCG's current pre-IND AS margins of around 14% are lower than industry averages.
KKR Investment Fuels Margin Upside Potential
Prabhudas Lilladher launched coverage on HealthCare Global Enterprises (HCG) with a 'BUY' rating and a ₹820 price target. This positive outlook is supported by HCG's 18% year-on-year Q4 consolidated EBITDA growth, reaching ₹1.25 billion. The brokerage highlighted HCG's asset-light strategy, which uses partnerships to build a capital-efficient and scalable business. KKR's recent strategic investment, along with the sale of the low-margin fertility business, is expected to significantly enhance operational and financial efficiencies. Although HCG's current margins at 14% trail industry peers, Prabhudas Lilladher believes KKR's involvement will accelerate growth. This acceleration is expected through adding more beds, improving the payor mix, and targeted marketing, all aimed at boosting margins. The firm projects an EBITDA compound annual growth rate (CAGR) of about 23% from FY26 to FY28. Currently, HCG trades at an attractive 19 times EV/EBITDA, adjusted for rentals and minority interests. The ₹820 target price suggests a valuation of 22 times FY28E EV/EBITDA. For the full year FY26, the company reported 15% revenue growth to ₹2,545 crore and a 19% rise in adjusted EBITDA to ₹471 crore, showing strong operational progress.
Valuation and Competitive Standing
HealthCare Global Enterprises (HCG) currently has a P/E ratio of 387.11, considerably higher than the sector average of 55.69. Competitors such as Apollo Hospitals Enterprises Ltd. and Fortis Healthcare Ltd. have P/E ratios of 63.83 and 75.26, respectively. Despite this high P/E, analysts generally rate HCG as a 'Strong Buy', with an average 12-month price target of ₹753.50, suggesting an upside potential of over 18%. This positive view is supported by forecasts of annual revenue growth averaging 18% for the next three years. KKR's acquisition of a controlling stake in February 2025 for $400 million is a significant development. KKR has a track record of value creation, demonstrated by their successful operational improvements at Max Healthcare, which led to substantial market cap growth. KKR's focus on operational enhancements, cost management, and strategic expansion aligns with HCG's goals for better capacity utilization and margin improvement. However, HCG's projected revenue growth of 13% for the next three years is slightly below the Indian Healthcare industry's forecast of 17% growth.
Margin Gaps and Valuation Concerns
While the brokerage report points to potential margin expansion, HCG's current pre-IND AS margins of approximately 14% remain below those of its industry peers. Achieving better margins will require significant operational improvements and strategic changes, now expected to be driven by KKR. The company's P/E ratio of 387.11 is exceptionally high compared to peers and the broader sector. For example, Apollo Hospitals and Fortis Healthcare trade at P/E ratios of 63.83 and 75.26. Even with a projected EBITDA CAGR of 23% from FY26 to FY28, the current valuation seems stretched. HCG's return on equity (ROE) has also been low, reported at 4.25% over the last three years. Additionally, promoter holding has decreased over the past three years, which can sometimes indicate internal caution. Despite a consensus 'Strong Buy' rating, the significant margin difference and high valuation metrics call for a careful approach. The company must achieve its projected growth and margin improvement targets to justify its current stock price and the ₹820 target.